Erica L. Mayer, MD, MPH

Erica L. Mayer, MD, MPH leads the Dana-Farber Breast Cancer in Pregnancy Program, overseeing the care of and research for of women diagnosed with breast cancer in pregnancy. She is the director of the Advanced Fellowships in Breast Oncology, and mentors students, residents, and fellows at Harvard Medical School and Dana-Farber.

Articles

Dr Mayer on Imlunestrant in HR+/HER2-Negative Advanced Breast Cancer Following Prior Endocrine Therapy

June 10th 2025

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

Dr Mayer on ESR1 Testing Methods in the SERENA-6 Study of Patients With ER+/HER2– Advanced Breast Cancer

June 5th 2025

Erica L. Mayer, MD, MPH, discusses ESR1 mutation detection by ctDNA liquid biopsy in the phase 3 SERENA-6 study.

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

December 14th 2024

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Ongoing Research and Unmet Needs in Patients With Breast Cancer and ESR1 Mutations

February 6th 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

SERENA-2: Camizestrant vs Fulvestrant in Advanced ER+/HER2- Breast Cancer

January 30th 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

The Role of Elacestrant in Breast Cancer

January 30th 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

EMERALD: Elacestrant in ER+/HER2- Advanced Breast Cancer

January 23rd 2024

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

PADA-1 Trial: ctDNA Monitoring for Acquired ESR1 Mutations in Advanced Breast Cancer

January 23rd 2024

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).

Overcoming Challenges in Biomarker Testing in Breast Cancer

January 16th 2024

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

Testing for ESR1 Mutations in Breast Cancer

January 16th 2024

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

December 1st 2023

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Mayer on the PACE Trial in HR+/HER2– Breast Cancer

January 12th 2023

Erica L. Mayer, MD, MPH, discusses findings from the phase 2 PACE trial in patients with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer.

Dr. Mayer on Tivozanib in Kidney and Breast Cancer

November 30th 2012

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

x